The Role of Prostate Specific Membrane Antigen and Pepsinogen C Tissue Expression as an Adjunctive Method to Prostate Cancer Diagnosis

Journal of Urology

Volumn 181, Issue 2, 2009, Pages 594-600

  Antunes, Alberto A ^a   Leite, Kátia R ^a,b   Sousa Canavez, Juliana M ^b   Camara Lopes, Luiz H ^b   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Genoa Biotechnology SA   (Brazil)

Author keywords

biopsy; diagnosis; gene expression; pepsinogen C; prostatic neoplasms

Indexed keywords

PEPSINOGEN II; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE; GENE EXPRESSION; GENETIC SELECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE CULTURE;

AGED; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPSINOGEN C; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 58149191227     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.10.007     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283
3. Parekh D.J., Ankerst D.P., Troyer D., Srivastava S., and Thompson I.M. Biomarkers for prostate cancer detection. J Urol 178 (2007) 2252
4. Welch H.G., Fisher E.S., Gottlieb D.J., and Barry M.J. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 99 (2007) 1395
5. Haas G.P., Delongchamps N.B., Jones R.F., Chandan V., Serio A.M., Vickers A.J., et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99 (2007) 1484
6. Roy C., Buy X., Lang H., Saussine C., and Jacqmin D. Contrast enhanced color Doppler endorectal sonography of prostate: efficiency for detecting peripheral zone tumors and role for biopsy procedure. J Urol 170 (2003) 69
7. Yuen J.S., Thng C.H., Tan P.H., Khin L.W., Phee S.J., Xiao D., et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171 (2004) 1482
8. Michiels S., Koscielny S., and Hill C. Interpretation of microarray data in cancer. Br J Cancer 96 (2007) 1155
9. Diamandis E.P., Nadkarni S., Bhaumik B., Abdelrahman A., Melegos D.N., Borchert G., et al. Immunofluorometric assay of pepsinogen C and preliminary clinical applications. Clin Chem 43 (1997) 1365
10. Kinoshita Y., Kuratsukuri K., Landas S., Imaida K., Rovito Jr. P.M., Wang C.Y., et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30 (2006) 628
11. Gery S., Sawyers C.L., Agus D.B., Said J.W., and Koeffler H.P. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 21 (2002) 4739
12. Rae J.M., Johnson M.D., Cordero K.E., Scheys J.O., Larios J.M., Gottardis M.M., et al. GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate 66 (2006) 886
13. Liu W., Shen X., Yang Y., Yin X., Xie J., Yan J., et al. Trihydrophobin 1 is a new negative regulator of A-Raf kinase. J Biol Chem 279 (2004) 10167
14. Abdul M., and Hoosein N.M. Gammopathy associated with advanced prostate carcinoma. Urol Res 23 (1995) 185
15. Epstein J.I., Amin M., Boccon-Gibod L., Egevad L., Humphrey P.A., Mikuz G., et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol, suppl. 216 (2005) 34
16. Pinto-Correia A.L., Sousa H., Fragoso M., Moreira-Dias L., Lopes C., Medeiros R., et al. Gastric cancer in a Caucasian population: role of pepsinogen C genetic variants. World J Gastroenterol 12 (2006) 5033
17. Díaz M., Rodríguez J.C., Sánchez J., Sánchez M.T., Martín A., Merino A.M., et al. Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma. Int J Biol Markers 17 (2002) 125
18. Reese J.H., McNeal J.E., Redwine E.A., Samloff I.M., and Stamey T.A. Differential distribution of pepsinogen II between the zones of the human prostate and the seminal vesicle. J Urol 136 (1986) 1148
19. Konishi N., Nakaoka S., Matsumoto K., Nakamura M., Kuwashima S., Hiasa Y., et al. Expression of pepsinogen II with androgen and estrogen receptors in human prostate carcinoma. Pathol Int 49 (1999) 203
20. Bander N.H., Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S., and Goldsmith S.J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591